Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atamparib in Advanced Solid Tumors and NSCLC
NCT07374419Phase 2Recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atamparib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Nerviano Medical Sciences. Started Mar 2026; status: recruiting.
02
Drugs
atamparib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07374419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374419.